Crossmark

Inhibition of DYRK1A proteolysis modifies its kinase specificity and rescues Alzheimer phenotype in APP/PS1 mice

Crossref DOI link: https://doi.org/10.1186/s40478-019-0678-6

Published Online: 2019-03-18

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Souchet, Benoît http://orcid.org/0000-0002-5078-2261
Audrain, Mickael

Billard, Jean Marie

Dairou, Julien

Fol, Romain

Orefice, Nicola Salvatore

Tada, Satoru

Gu, Yuchen

Dufayet-Chaffaud, Gaelle

Limanton, Emmanuelle

Carreaux, François

Bazureau, Jean-Pierre

Alves, Sandro

Meijer, Laurent

Janel, Nathalie

Braudeau, Jérôme

Cartier, Nathalie
License Information

Text and Data Mining valid from 2019-03-18
More Information

Article History

Received: 4 January 2019

Accepted: 14 February 2019

First Online: 18 March 2019

Ethics approval and consent to participate

: This research was performed in compliance with relevant laws and institutional guidelines and approved by the appropriate institutional committees. All patients provided informed written consent. All experiments were conducted in accordance with the ethical standards of French, German, and European regulations (European Communities Council Directive of 24 November 1986). The supervisor of in vivo studies (J Braudeau) received official authorization from the French Ministry of Agriculture to carry out research and experimentation on animals (authorization number APAFIS#4449–2,016,031,012,491,697).

: The authors declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.